- Conditions
- Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- anti-thymocyte globulin, busulfan, cyclosporine, melphalan, methotrexate, methylprednisolone, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, umbilical cord blood transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 481–504
of 1,172
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Undifferentiated Leukemia, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Myelomonocytic Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Juvenile Myelomonocytic Leukemia, Mast Cell Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myeloid/NK-cell Acute Leukemia, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Primary Systemic Amyloidosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Renal Cell Cancer, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage II Multiple Myeloma, Stage III Multiple Myeloma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenström Macroglobulinemia
- Interventions
- total-body irradiation, fludarabine phosphate, cyclosporine, mycophenolate mofetil, nonmyeloablative allogeneic hematopoietic stem cell transplantation, donor lymphocytes, peripheral blood stem cell transplantation, laboratory biomarker analysis
- Radiation · Drug · Procedure + 2 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 74 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Acute Graft-Versus-Host Disease (Gvhd) Grade, Hematopoietic Cell Transplantation, Fecal Microbiota Transplant
- Interventions
- Fecal Microbiota Transplant
- Biological
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hematological Malignancies, Graft-versus-Host Disease (GVHD)
- Interventions
- Attenuated-dose Cyclophosphamide, High-dose Cyclophosphamide, Sirolimus, Mycophenolate Mofetil (MMF)
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Leukemia
- Interventions
- filgrastim, cladribine, cytarabine, etoposide, methotrexate, mitoxantrone hydrochloride, therapeutic hydrocortisone, allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2008
- U.S. locations
- 35
- States / cities
- Long Beach, California • Los Angeles, California • Orange, California + 27 more
- Conditions
- Hematological Malignancies
- Interventions
- fostamatinib
- Drug
- Lead sponsor
- Stefanie Sarantopoulos, MD, PhD.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Hematological Malignancies
- Interventions
- Haploidentical Allogeneic Transplantation
- Device
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Graft Vs Host Disease, GVHD
- Interventions
- Pacritinib, Sirolimus, Tacrolimus, Allogenic hematopoietic cell transplant (alloHCT)
- Drug · Procedure
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Minneapolis, Minnesota
- Conditions
- Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer
- Interventions
- galinpepimut-S, pembrolizumab, Montanide, GM-CSF
- Biological · Other
- Lead sponsor
- Sellas Life Sciences Group
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 12
- States / cities
- Santa Rosa, California • Whittier, California • Miami, Florida + 9 more
- Conditions
- Myeloproliferative Disorders, Blood Cancer, Myelodysplastic Syndromes
- Interventions
- Total Lymphoid Irradiation (TLI), Anti-Thymocyte Globulin as Conditioning (ATG)
- Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 49 Years to 75 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2015
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Kidney Cancer
- Interventions
- alemtuzumab, graft-versus-tumor induction therapy, cyclophosphamide, fludarabine phosphate, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- Activated marrow infiltrating lymphocytes, Allogeneic Myeloma Vaccine, Cyclophosphamide, Filgrastim, Leukapheresis, Melphalan, Autologous stem cell transplant
- Biological · Drug · Procedure
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myeloproliferative Neoplasms, Myelofibrosis, Myelodysplasia, Refractory Anemia, High Risk Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Diffuse Large Cell Non Hodgkins Lymphoma, Lymphoblastic Lymphoma, Burkitt Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult, Multiple Myeloma, Juvenile Myelomonocytic Leukemia, Biphenotypic/Undifferentiated/Prolymphocytic Leukemias, MRD Positive Leukemia, Natural Killer Cell Malignancies, Acquired Bone Marrow Failure Syndromes
- Interventions
- HSCT with TBI Regimen, HSCT with Non-TBI Regimen
- Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Graft Versus Host Disease
- Interventions
- D-SQUAME Skin Sampling Discs
- Device
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 3 Months to 30 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Lymphoma
- Interventions
- NK Cell infusion using CD56 monoclonal antibody, Donor Apheresis
- Device · Procedure
- Lead sponsor
- David Rizzieri, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Acute Leukemia, Chronic Leukemia, Myelodysplastic Syndrome, Non-Hodgkins Lymphoma
- Interventions
- total-body irradiation (TBI), thiotepa, fludarabine phosphate, melphalan, anti-thymocyte globulin, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, laboratory biomarker analysis
- Radiation · Drug · Biological + 2 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Up to 19 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cutaneous T-cell Lymphoma, T-Prolymphocytic Leukemia, T-Large Granulocytic Leukemia, T-Lymphoblastic Leukemia/Lymphoma, Peripheral T-Cell Lymphoma
- Interventions
- Romidepsin, Busulfan, Fludarabine, Stem Cell Transplant, Thymoglobulin
- Drug · Procedure
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Leukemia/Lymphoma, Cutaneous T Cell Lymphoma, ATLL
- Interventions
- Not listed
- Lead sponsor
- Kyowa Kirin, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
- Interventions
- VOR33, Mylotarg
- Biological · Drug
- Lead sponsor
- Vor Biopharma
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 14
- States / cities
- La Jolla, California • Stanford, California • Miami, Florida + 10 more
- Conditions
- Acute Myeloid Leukemia or Myelodysplastic Syndromes
- Interventions
- APR-246
- Drug
- Lead sponsor
- Aprea Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 7
- States / cities
- Tampa, Florida • Baltimore, Maryland • Boston, Massachusetts + 3 more
- Conditions
- Hematologic Malignancies
- Interventions
- Allogeneic donor TCRαβ+/CD19+ cell-depleted peripheral blood mononuclear cells
- Device
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- HIV, Hematologic Malignancies
- Interventions
- RIC, GVHD prophylaxis, allo HCT, Plerixafor, Maraviroc
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years to 120 Years
- Enrollment
- 265 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hematopoietic Stem Cell Transplantation
- Interventions
- Tacrolimus, Methotrexate, Tocilizumab
- Drug
- Lead sponsor
- William R. Drobyski, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Juvenile Myelomonocytic Leukemia
- Interventions
- tipifarnib, isotretinoin, fludarabine phosphate, cytarabine, radiation therapy, cyclophosphamide, anti-thymocyte globulin, allogeneic bone marrow transplantation, double-unit umbilical cord blood transplantation, umbilical cord blood transplantation, laboratory biomarker analysis
- Drug · Radiation · Biological + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 18 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Arcadia, California